Gerresheimer AG (ETR: GXI)
Market Cap | 2.75B |
Revenue (ttm) | 2.01B |
Net Income (ttm) | 114.30M |
Shares Out | 34.54M |
EPS (ttm) | 3.31 |
PE Ratio | 24.08 |
Forward PE | 14.61 |
Dividend | 1.25 (1.57%) |
Ex-Dividend Date | Jun 6, 2024 |
Volume | 89,093 |
Open | 80.65 |
Previous Close | 81.10 |
Day's Range | 76.65 - 80.75 |
52-Week Range | 76.10 - 111.20 |
Beta | 0.94 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Oct 10, 2024 |
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufactu... [Read more]
Financial Performance
In 2023, Gerresheimer AG's revenue was 1.99 billion, an increase of 9.54% compared to the previous year's 1.82 billion. Earnings were 116.13 million, an increase of 20.81%.
Financial StatementsNews
EQS-News: Solar power for Gerresheimer site in Momignies, Belgium
EQS-News: Gerresheimer AG / Key word(s): ESG Solar power for Gerresheimer site in Momignies, Belgium 14.10.2024 / 11:00 CET/CEST The issuer is solely responsible for the content of this announcement. ...
Gerresheimer AG (GRRMY) Q3 2024 Earnings Call Highlights: Navigating Growth Amid Challenges
Gerresheimer AG (GRRMY) Q3 2024 Earnings Call Highlights: Navigating Growth Amid Challenges
Gerresheimer shares jump as activist investor buys over 5% stake
Gerresheimer's shares rose as much as 6.8% on Wednesday after a regulatory filing showed activist investor Ricky Chad Sandler had bought a 5.43% stake in German medical packaging maker.
Gerresheimer AG Slashes Growth Forecast for 2024 and 2025
Gerresheimer AG revises its 2024 and 2025 growth forecasts due to slower market recovery and Hurricane Helene's impact on its US vial plant. Join their conference call on September 30, 2024, for more ...
EQS-Adhoc: Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025
EQS-Ad-hoc: Gerresheimer AG / Key word(s): Change in Forecast/Development of Sales Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025 30-Sep-2024 / 16:21 CET/CEST Disclosure of an inside...
Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together w...
EQS-News: SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU”
EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Agreement SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU” 26.09.2024 / 12:30 CET/CEST The issuer is...
EQS-News: Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU”
EQS-News: Gerresheimer AG / Key word(s): Alliance Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU” 26.09.2024 / 12:30 CET/CEST The issuer is solely respon...
Fill Finish Manufacturing Strategic Business Report 2023-2030 with Focus on 45+ Select Players Including Bausch+Strobel Maschinenfabrik Ilshofen, Becton, Dickinson and Co, & Gerresheimer Among Others – ResearchAndMarkets.com
DUBLIN — The “Fill Finish Manufacturing – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Fill Finish Manufacturing is estimated at ...
Gerresheimer AG (GRRMF) Q2 2024 Earnings Call Transcript
Gerresheimer AG (OTCPK:GRRMF) Q2 2024 Earnings Conference Call July 11, 2024 4:00 AM ET Company Participants Guido Pickert - IR Dietmar Siemssen - CEO Bernd Metzner - CFO Conference Call Participants ...
Gerresheimer core profit meets forecast on weight-loss drug deals pipeline
Germany's Gerresheimer posted second-quarter adjusted core profit in line with market expectations on Thursday, driven by the deal pipeline for its plastics and devices segment, which supplies makers ...
Gerresheimer supplies 'key players' in GLP-1 drugs market, CEO says
German packaging and medical equipment maker Gerresheimer is contracted to supply key players in the market for GLP-1 weight loss drugs, its CEO Dietmar Siemssen said on Thursday.
Gerresheimer expects sales boost from burgeoning obesity drugs sector
German packaging and medical equipment maker Gerresheimer on Thursday posted adjusted first-quarter core profit in line with expectations of analysts polled by Vara Research, driven by the plastics an...
Gerresheimer Makes Solid Start to the Financial Year 2024
Organic growth: Revenues +2.8%, adjusted EBITDA +5.9% Capacity expansion in the Americas, Europe and Asia progresses according to plan Guidance confirmed DUSSELDORF, GERMANY / ACCESSWIRE / April 11, 2...
Gerresheimer CEO dubs weight-loss drugs a meaningful positive catalyst
Dietmar Siemssen – the chief executive of Gerresheimer AG (ETR: GXI) expects strong demand for weight-loss drugs to be a meaningful tailwind for his company. Weight-loss drugs to boost $GXI revenue gr...
Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says
Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company's revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes a...
Gerresheimer AG (GRRMF) Q4 2023 Earnings Call Transcript
Gerresheimer AG (GRRMF) Q4 2023 Earnings Call Transcript
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Organic revenue growth in 2023: +10.4% Organic adjusted EBITDA growth in 2023: +17.5% Favorable product mix boosts profitability High order backlog and global capacity expansion secure profitable grow...
Gerresheimer awarded EcoVadis Gold status again
- Gerresheimer among the top 5% of assessed businesses - Total score increases to 72/100 points - Status demonstrates consistent implementation of CSR strategy DUESSELDORF, Germany , Oct. 18, 2023 ...
Gerresheimer AG (GRRMF) Q3 2023 Earnings Call Transcript
Gerresheimer AG (OTCPK:GRRMF) Q3 2023 Earnings Conference Call October 5, 2023 4:00 AM ET Company Participants Bernhard Wolf - Corporate Senior Director, Investor Relations Dietmar Siemssen - Chief Ex...
Gerresheimer AG: Gerresheimer on Track to Another Strong Financial Year
Organic revenue growth of 12.6% in the first nine months of the financial year 2023 Adjusted EBITDA up organically by 20.6% Order intake at record high: new orders for syringes and pens for GLP-1 drug...
Gerresheimer AG: Gerresheimer Continues Dynamic Growth in First Half of 2023
Organic revenue growth of 16.6% in first half of 2023 Adjusted EBITDA up 23.0% organically Production capacities expanded in Europe, the United States, and Mexico Guidance for full year 2023 confirmed...
Gerresheimer AG (GRRMF) Q1 2023 Earnings Call Transcript
Gerresheimer AG (OTCPK:GRRMF) Q1 2023 Earnings Conference Call April 6, 2023 4:00 AM ET Company Participants Carolin Nadilo - Head of Investor Relations Dietmar Siemssen - Chief Executive Officer Dr. ...
Gerresheimer AG (GRRMF) Q4 2022 Earnings Call Transcript
Gerresheimer AG (OTCPK:GRRMF) Q4 2022 Results Conference Call February 23, 2023 4:00 AM ET Company Participants Carolin Nadilo - Head of Investor Relations Dietmar Siemssen - Chief Executive Officer D...
Gerresheimer AG (GRRMF) Q3 2022 Earnings Call Transcript
Gerresheimer AG (OTCPK:GRRMF) Q3 2022 Earnings Conference Call October 12, 2022 4:00 AM ET Company Participants Carolin Nadilo - Head of Investor Relations Dietmar Siemssen - Chief Executive Officer B...